Citations Report

Articles published in Clinical Schizophrenia & Related Psychoses have been cited by esteemed scholars and scientists all around the world. Clinical Schizophrenia & Related Psychoses has got h-index 41, which means every article in Clinical Schizophrenia & Related Psychoses has got 41 average citations.

Following are the list of articles that have cited the articles published in Clinical Schizophrenia & Related Psychoses.

Capuano, Agnieszka Suchocka, Achour Karar, Aurélie Georgin, Annick Ponseti Gaillochon, and Samir Bouyakoub. "Identification émotionnelle et entraînement aux compétences sociales chez des patients atteints de schizophrénie et de troubles bipolaires." Journal de Thérapie Comportementale et Cognitive 26, no. 1 (2016): 21-31.

Widschwendter, Christian G., Georg Kemmler, Maria A. Rettenbacher, Nursen Yalcin-Siedentopf, and Alex Hofer. "Subjective well-being, drug attitude, and changes in symptomatology in chronic schizophrenia patients starting treatment with new-generation antipsychotic medication." BMC psychiatry 18, no. 1 (2018): 1-9.

Wang, Bing, Wentao Jiang, Weiqiang Yan, Jianhong Tian, Jianxing Xu, Yulin Li, Yanzhen Zhao, Yi Dai, Guanxun Cheng, and Gangqiang Hou. "Clinical characteristics and neuroimaging findings of seven patients with Dyke Davidoff Masson syndrome." BMC neurology 21, no. 1 (2021): 1-9.

Kumari, Pooja, Harim Mohsin, and Maju Mathew Koola. "Dyke-Davidoff-Masson syndrome presenting with bipolar I mania with psychosis." Indian journal of psychiatry 60, no. 1 (2018): 149.

Sordia-Ramírez, José, Adrián Infante-Valenzuela, Iván de Jesús Hernández-Galarza, and Antonio Costilla-Esquivel. "Neuropsychiatric symptoms in a patient with Dyke–Davidoff–Masson syndrome and systemic lupus erythematosus: a case report." Journal of medical case reports 13, no. 1 (2019): 1-6.

Reiter, Eva, Beatrice Heim, Christoph Scherfler, Christoph Mueller, Michael Nocker, Jean?Pierre Ndayisaba, Wolfgang Loescher et al. "Clinical heterogeneity in cerebral hemiatrophy syndromes." Movement disorders clinical practice 3, no. 4 (2016): 382-388.

Lake, James. "Integrative management of schizophrenia." Psychiatric Times 31, no. 5 (2014): 46-46.

Khalifeh, Anas Husam. "Omega-3 Fatty Acids as Complementary and Alternative Medicine for Depression: Literature Review." American Journal of Nursing 4, no. 3 (2016): 69-73.

Dassanayake, Tharaka L., Chanaka N. Kahathuduwa, and Vajira S. Weerasinghe. "L-theanine improves neurophysiological measures of attention in a dose-dependent manner: a double-blind, placebo-controlled, crossover study." Nutritional Neuroscience (2020): 1-11.

Gharoon, Niloufar, and Krishna R. Pagilla. "Critical review of effluent dissolved organic nitrogen removal by soil/aquifer-based treatment systems." Chemosphere (2020): 129406.

Jeppesen, Rose, Rune HB Christensen, Emilie MJ Pedersen, Merete Nordentoft, Carsten Hjorthøj, Ole Köhler-Forsberg, and Michael E. Benros. "Efficacy and safety of anti-inflammatory agents in treatment of psychotic disorders-a comprehensive systematic review and meta-analysis." Brain, Behavior, and Immunity (2020).

Sholler, Dennis J., Marilyn A. Huestis, Benjamin Amendolara, Ryan Vandrey, and Ziva D. Cooper. "Therapeutic potential and safety considerations for the clinical use of synthetic cannabinoids." Pharmacology Biochemistry and Behavior (2020): 173059.

Sakamoto, Filipe Lopes, Rodrigo Metzker Pereira Ribeiro, Allain Amador Bueno, and Heitor Oliveira Santos. "Psychotropic effects of L-theanine and its clinical properties: From the management of anxiety and stress to a potential use in schizophrenia." Pharmacological research 147 (2019): 104395.

Rajagopal, L., D. Soni, and H. Y. Meltzer. "Neurosteroid pregnenolone sulfate, alone, and as augmentation of lurasidone or tandospirone, rescues phencyclidine-induced deficits in cognitive function and social interaction." Behavioural brain research 350 (2018): 31-43.

Howells, Fleur M., David G. Kingdon, and David S. Baldwin. "Current and potential pharmacological and psychosocial interventions for anxiety symptoms and disorders in patients with schizophrenia: structured review." Human Psychopharmacology: Clinical and Experimental (2017).

Ogawa, Shintaro, Miho Ota, Jun Ogura, Koichi Kato, and Hiroshi Kunugi. "Effects of l-theanine on anxiety-like behavior, cerebrospinal fluid amino acid profile, and hippocampal activity in Wistar Kyoto rats." Psychopharmacology 235, no. 1 (2018): 37-45.

Leweke, F. Markus, Juliane K. Mueller, Bettina Lange, Stefan Fritze, Cristina E. Topor, Dagmar Koethe, and Cathrin Rohleder. "Role of the endocannabinoid system in the pathophysiology of schizophrenia: implications for pharmacological intervention." CNS drugs 32, no. 7 (2018): 605-619.

Remington, Gary, George Foussias, Gagan Fervaha, Ofer Agid, Hiroyoshi Takeuchi, Jimmy Lee, and Margaret Hahn. "Treating negative symptoms in schizophrenia: an update." Current treatment options in psychiatry 3, no. 2 (2016): 133-150.

Samalin, Ludovic, Ricardo Garay, Ahcène Ameg, and Pierre-Michel Llorca. "Olanzapine pamoate for the treatment of schizophrenia–a safety evaluation." Expert opinion on drug safety 15, no. 3 (2016): 403-411.